Literature DB >> 3389589

Percutaneous endoscopic gastrostomy in the cancer patient.

T A Stellato1, M W Gauderer.   

Abstract

A retrospective analysis of all patients with malignancy undergoing percutaneous endoscopic gastrostomy (PEG) was undertaken. PEG was attempted in 42 cancer patients from a total of 142 patients and successful in 38 (90.5%). The success rate in completing this procedure in cancer patients was significantly less than in noncancer patients (P = 0.04). The most common malignancy was oral-pharyngeal carcinoma (29%). Survival data was available in 35 of 38 patients (92%). Three patients died in less than one month. Forty six per cent of the patients survived three months or longer and 20 per cent 1 year or longer. The majority of the patients (68%) were able to return home after the PEG. There was no mortality related to the procedure. Local anesthesia was used in 95 per cent of the procedures. The major concerns derived from the study are the short-term survival in a small number of patients and aspiration in selective patients. Attempts should be made to identify these patients and avoid PEG since its benefits will be limited. When used selectively, PEG can improve the quality of life of the cancer patient.

Entities:  

Mesh:

Year:  1988        PMID: 3389589

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  4 in total

Review 1.  Endoscopic intervention for enteral access.

Authors:  T A Stellato
Journal:  World J Surg       Date:  1992 Nov-Dec       Impact factor: 3.352

Review 2.  Percutaneous endoscopic gastrostomy. Results in 316 patients and review of literature.

Authors:  R E Miller; B Castlemain; F J Lacqua; D P Kotler
Journal:  Surg Endosc       Date:  1989       Impact factor: 4.584

Review 3.  Abdominal wall metastasis following percutaneous endoscopic gastrostomy.

Authors:  G Becker; C F Hess; K E Grund; W Hoffmann; M Bamberg
Journal:  Support Care Cancer       Date:  1995-09       Impact factor: 3.603

4.  Survival estimates for patients with abnormal swallowing studies.

Authors:  M E Cowen; S L Simpson; T E Vettese
Journal:  J Gen Intern Med       Date:  1997-02       Impact factor: 5.128

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.